SOUTH SAN FRANCISCO, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 32nd International Symposium on ALS/MND ...
Metagenomi is editing its pipeline, choosing to seek a partner for a program Moderna dropped and axing its amyotrophic lateral sclerosis (ALS) activities in response to setbacks at a competitor. The ...
MEDICAL SERVICE PROGRAM THAT EXETER HOSPITAL IS ENDING. SO RIGHT NOW THERE ARE 13 TOWNS CONTRACTED WITH THE EXETER HOSPITAL ALS PROGRAM. ON MARCH 21ST, THAT PROGRAM WILL BE OFFICIALLY CLOSING. SO THE ...
- All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a biotechnology ...
Takeda Pharmaceuticals struck a deal with AcuraStem to purchase its amyotrophic lateral sclerosis (ALS) treatment program on Monday. Per terms of the transaction, the Japanese pharma giant will ...
Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and neurological conditions, announced the company has ...
LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results